Alzheimer Disease, Familial or Cerebral Amyloid Angiopathy via the APP Gene

  • Summary and Pricing
  • Clinical Features and Genetics
  • Citations
  • Methods
  • Ordering/Specimens
Order Kits

NGS Sequencing

Test Code Test Copy GenesIndividual Gene PriceCPT Code Copy CPT Codes
4557 APP$640.00 81406 Add to Order
Pricing Comment

Our most cost-effective testing approach is NextGen sequencing with Sanger sequencing supplemented as needed to ensure sufficient coverage and to confirm NextGen calls that are pathogenic, likely pathogenic or of uncertain significance. If, however, full gene Sanger sequencing only is desired (for purposes of insurance billing or STAT turnaround time for example), please see link below for Test Code, pricing, and turnaround time information.

For Sanger Sequencing click here.
Targeted Testing

For ordering targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 20 days.

Clinical Sensitivity

Point variants in the APP gene are identified in ~ 15% of familial Alzheimer disease cases (Wallon et al. 2012; Janssen et al. 2003). Detection rate of pathogenic variants in the APP gene in cerebral amyloid angiopathy is unknown as no large-scale molecular studies have been done. APP-related cerebral amyloid angiopathy is the most common form of cerebral amyloid angiopathy.

See More

See Less

Deletion/Duplication Testing via aCGH

Test Code Test Copy GenesIndividual Gene PriceCPT Code Copy CPT Codes
600 APP$990.00 81479 Add to Order
Pricing Comment

# of Genes Ordered

Total Price









Over 100

Call for quote

Targeted Testing

For ordering targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 20 days.

Clinical Features

Familial Alzheimer disease (FAD) is a neurodegenerative disorder characterized by onset of dementia at a relatively young age. Dementia initially presents in FAD patients as short term memory problems or disorientation between 30 and 60 years of age. Cognitive decline is observed over the next 10-20 years with apraxia, progressive memory loss and impaired spatial skills being common presentations (Wallon et al. 2012). Motor disturbances such as cerebellar ataxia and spastic paraparesis are also observed in a subset of patients. The key neuropathology of FAD includes: amyloid plaques, neurofibrillary tangles, neuronal loss and brain atrophy (Wu et al. 2012). An important feature of the FAD diagnosis is that an individual has at least one affected family member. Cerebral amyloid angiopathy APP-related (CAA): Select pathogenic variants in the APP gene can also cause severe cerebral amyloid angiopathy, where amyloid fibrils accumulate in blood vessels and can lead to cerebral hemorrhage, stroke and progressive dementia. Clinical and neuropathologic symptoms of cerebral amyloid angiopathy overlap with Alzheimer disease. Several variants such as Dutch, Iowa, Italian, Flemish, Arctic, etc. have been reported (Revesz et al. 2009; Biffi and Greenberg 2011; Kumar-Singh et al 2002).


Familial Alzheimer disease is inherited in an autosomal dominant manner and can be caused by pathogenic variants in the APP gene. Almost all reported APP pathogenic variants are missense, frameshift and small deletion variants contained within Exons 16 and 17 of the APP gene, except rare large duplications. These variants disrupt processing of APP into mature amyloid-beta protein (Janssen et al. 2003; Mullan et al. 1992; Tomiyama et al. 2008). Large duplications encompassing the entire APP gene have also been identified in FAD patients (McNaughton et al. 2012). A rare recessive pathogenic variant in the APP gene was reported to cause FAD (Di Fede et al. 2009). Cerebral amyloid angiopathy APP-related is inherited in an autosomal dominant manner. The causative pathogenic variants in cerebral amyloid angiopathy are missense variants and large duplications in APP gene. Most pathogenic variants such as Dutch, Iowa, Italian, Flemish Arctic etc. are concentrated in exon 17 (Biffi and Greenberg 2011; Sleegers et al 2006; Kumar-Singh et al 2002). APP encodes amyloid-beta precursor protein (APP). Numerous studies suggest that APP has a trophic function and it may be involved in neuronal stem cell development, neuronal survival, neurite outgrowth, neurorepair and memory formation (Dawkins and Small 2014; Bourdet et al. 2015). APP protein is post-translationally processed into two amyloid-beta isoforms: AB40 and AB42. The gamma-secretase complex that processes APP contains the proteins PSEN1 and PSEN2, which also play a role in FAD pathogenesis (Sua'rez-Calvet et al. 2014). Pathogenic variants in the APP gene that disrupt the gamma-secretase cleavage site can result in increased levels of the AB42 isoform relative to the AB40 isoform. This imbalance promotes amyloid-beta aggregation (Kumar-Singh et al. 2000). Pathogenic variants in the APP gene also result in hyperphosphorylation of the microtubule associated protein, tau (Umeda et al. 2014). Hyperphosphorylation causes tau to form long filaments and neurofibrillary tangles. The presence of amyloid plaques and neurofibrillary tangles leads to neuroinflammation and neuronal cell death, which underlie the dementia phenotype.

Testing Strategy

For this NextGen test, the full coding regions plus ~10 bp of non-coding DNA flanking each exon are sequenced for the gene listed below. Sequencing is accomplished by capturing specific regions with an optimized solution-based hybridization kit, followed by massively parallel sequencing of the captured DNA fragments. Additional Sanger sequencing is performed for any regions not captured or with insufficient number of sequence reads. All pathogenic, likely pathogenic, or variants of uncertain significance are confirmed by Sanger sequencing.

Indications for Test

APP testing should be considered for individuals with early onset dementia who have at least one affected family member and for which no PSEN1 mutation has been identified (Loy et al. 2013). APP sequencing can also be used to determine carrier status of individuals for a known familial mutation. APP testing is also recommended for individual who are suspected to have cerebral amyloid angiopathy.


Official Gene Symbol OMIM ID
APP 104760
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Cerebral Amyloid Angiopathy, App-Related 605714

Related Tests

Alzheimer's Disease, Familial via the APP Gene, Exons 16 and 17
Autism Spectrum Disorders and Intellectual Disability (ASD-ID) Comprehensive Sequencing Panel with CNV Detection


Genetic Counselors
  • Biffi A., Greenberg SM. 2011. Journal of Clinical Neurology (seoul, Korea). 7: 1-9. PubMed ID: 21519520
  • Bourdet I. et al. 2015. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 1043-51. PubMed ID: 25609621
  • Dawkins E., Small DH. 2014. Journal of Neurochemistry. 129: 756-69. PubMed ID: 24517464
  • Di Fede G. et al. 2009. Science. 323: 1473-7. PubMed ID: 19286555
  • Janssen JC. et al. 2003. Neurology. 60: 235-9 PubMed ID: 12552037
  • Kumar-Singh S. et al. 2000. Human Molecular Genetics. 9: 2589-98. PubMed ID: 11063718
  • Kumar-Singh S. et al. 2002. The American Journal of Pathology. 161: 507-20. PubMed ID: 12163376
  • Loy CT. et al. 2014. Lancet. 383: 828-40. PubMed ID: 23927914
  • McNaughton D. et al. 2012. Neurobiology of Aging. 33: 426.e13-426.e21 PubMed ID: 21193246
  • Mullan M. et al. 1992. Nature Genetics. 1: 345-7. PubMed ID: 1302033
  • Revesz T. et al. 2009. Acta Neuropathologica. 118: 115-130 PubMed ID: 19225789
  • Sleegers K. et al. 2006. Brain. 129: 2977-2983 PubMed ID: 16921174
  • Suárez-Calvet M. et al. 2014. Journal of Neurochemistry. 128: 330-9 PubMed ID: 24117942
  • Tomiyama T. et al. 2008. Annals of Neurology. 63: 377-87. PubMed ID: 18300294
  • Umeda T. et al. 2014. Acta Neuropathologica. 127: 685-98. PubMed ID: 24531886
  • Wallon D. et al. 2012. Journal of Alzheimer's Disease. 30: 847–856 PubMed ID: 22475797
  • Wu L. et al. 2012. The Canadian Journal of Neurological Sciences. 39: 436–445 PubMed ID: 22728850
Order Kits

NextGen Sequencing using PG-Select Capture Probes

Test Procedure

We use a combination of Next Generation Sequencing (NGS) and Sanger sequencing technologies to cover the full coding regions of the listed genes plus ~20 bases of non-coding DNA flanking each exon.  As required, genomic DNA is extracted from the patient specimen.  For NGS, patient DNA corresponding to these regions is captured using an optimized set of DNA hybridization probes.  Captured DNA is sequenced using Illumina’s Reversible Dye Terminator (RDT) platform (Illumina, San Diego, CA, USA).  Regions with insufficient coverage by NGS are covered by Sanger sequencing.  All pathogenic, likely pathogenic, or variants of uncertain significance are confirmed by Sanger sequencing.

For Sanger sequencing, Polymerase Chain Reaction (PCR) is used to amplify targeted regions.  After purification of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit.  PCR products are resolved by electrophoresis on an ABI 3730xl capillary sequencer.  In nearly all cases, cycle sequencing is performed separately in both the forward and reverse directions.

Patient DNA sequence is aligned to the genomic reference sequence for the indicated gene region(s). All differences from the reference sequences (sequence variants) are assigned to one of five interpretation categories, listed below, per ACMG Guidelines (Richards et al. 2015).

(1) Pathogenic Variants
(2) Likely Pathogenic Variants
(3) Variants of Uncertain Significance
(4) Likely Benign Variants
(5) Benign, Common Variants

Human Genome Variation Society (HGVS) recommendations are used to describe sequence variants (  Rare variants and undocumented variants are nearly always classified as likely benign if there is no indication that they alter protein sequence or disrupt splicing.

Analytical Validity

As of March 2016, 6.36 Mb of sequence (83 genes, 1557 exons) generated in our lab was compared between Sanger and NextGen methodologies. We detected no differences between the two methods. The comparison involved 6400 total sequence variants (differences from the reference sequences). Of these, 6144 were nucleotide substitutions and 256 were insertions or deletions. About 65% of the variants were heterozygous and 35% homozygous. The insertions and deletions ranged in length from 1 to over 100 nucleotides.

In silico validation of insertions and deletions in 20 replicates of 5 genes was also performed. The validation included insertions and deletions of lengths between 1 and 100 nucleotides. Insertions tested in silico: 2200 between 1 and 5 nucleotides, 625 between 6 and 10 nucleotides, 29 between 11 and 20 nucleotides, 25 between 21 and 49 nucleotides, and 23 at or greater than 50 nucleotides, with the largest at 98 nucleotides. All insertions were detected. Deletions tested in silico: 1813 between 1 and 5 nucleotides, 97 between 6 and 10 nucleotides, 32 between 11 and 20 nucleotides, 20 between 21 and 49 nucleotides, and 39 at or greater than 50 nucleotides, with the largest at 96 nucleotides. All deletions less than 50 nucleotides in length were detected, 13 greater than 50 nucleotides in length were missed. Our standard NextGen sequence variant calling algorithms are generally not capable of detecting insertions (duplications) or heterozygous deletions greater than 100 nucleotides. Large homozygous deletions appear to be detectable.   

Analytical Limitations

Interpretation of the test results is limited by the information that is currently available.  Better interpretation should be possible in the future as more data and knowledge about human genetics and this specific disorder are accumulated.

When Sanger sequencing does not reveal any difference from the reference sequence, or when a sequence variant is homozygous, we cannot be certain that we were able to detect both patient alleles.  Occasionally, a patient may carry an allele which does not amplify, due to a large deletion or insertion.   In these cases, the report will contain no information about the second allele.  Our Sanger and NGS Sequencing tests are generally not capable of detecting Copy Number Variants (CNVs).

We sequence all coding exons for each given transcript, plus ~20 bp of flanking non-coding DNA for each exon.  Test reports contain no information about other portions of the gene, such as regulatory domains, deep intronic regions or any currently uncharacterized alternative exons.

In most cases, we are unable to determine the phase of sequence variants.  In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.

Our ability to detect minor sequence variants due to somatic mosaicism is limited.  Sequence variants that are present in less than 50% of the patient’s nucleated cells may not be detected.

Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during PCR.

Unless otherwise indicated, DNA sequence data is obtained from a specific cell-type (usually leukocytes from whole blood).   Test reports contain no information about the DNA sequence in other cell-types.

We cannot be certain that the reference sequences are correct.

Rare, low probability interpretations of sequencing results, such as for example the occurrence of de novo mutations in recessive disorders, are generally not included in the reports.

We have confidence in our ability to track a specimen once it has been received by PreventionGenetics.  However, we take no responsibility for any specimen labeling errors that occur before the sample arrives at PreventionGenetics.

Deletion/Duplication Testing via Array Comparative Genomic Hybridization

Test Procedure

Equal amounts of genomic DNA from the patient and a gender matched reference sample are amplified and labeled with Cy3 and Cy5 dyes, respectively. To prevent any sample cross contamination, a unique sample tracking control is added into each patient sample. Each labeled patient product is then purified, quantified, and combined with the same amount of reference product. The combined sample is loaded onto the designed array and hybridized for at least 22-42 hours at 65°C. Arrays are then washed and scanned immediately with 2.5 µM resolution. Only data for the gene(s) of interest for each patient are extracted and analyzed.

Analytical Validity

PreventionGenetics' high density gene-centric custom designed aCGH enables the detection of relatively small deletions and duplications within a single exon of a given gene or deletions and duplications encompassing the entire gene. PreventionGenetics has established and verified this test's accuracy and precision.

Analytical Limitations

Our dense probe coverage may allow detection of deletions/duplications down to 100 bp; however due to limitations and probe spacing this cannot be guaranteed across all exons of all genes. Therefore, some copy number changes smaller than 100-300 bp within a targeted large exon may not be detected by our array.

This array may not detect deletions and duplications present at low levels of mosaicism or those present in genes that have pseudogene copies or repeats elsewhere in the genome.

aCGH will not detect balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype.

Breakpoints, if occurring outside the targeted gene, may be hard to define.

The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory.

Order Kits

Ordering Options

myPrevent - Online Ordering
  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.


(Delivery accepted Monday - Saturday)

  • Collect 3 ml -5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10 ml -20 ml of whole blood.
  • For small babies, we require a minimum of 1 ml of blood.
  • Only one blood tube is required for multiple tests.
  • Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
  • During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
  • In cold weather, include an unfrozen ice pack in the shipping container as insulation.
  • At room temperature, blood specimen is stable for up to 48 hours.
  • If refrigerated, blood specimen is stable for up to one week.
  • Label the tube with the patient name, date of birth and/or ID number.


(Delivery accepted Monday - Saturday)

  • Send in screw cap tube at least 5 µg -10 µg of purified DNA at a concentration of at least 20 µg/ml for NGS and Sanger tests and at least 5 µg of purified DNA at a concentration of at least 100 µg/ml for gene-centric aCGH, MLPA, and CMA tests, minimum 2 µg for limited specimens.
  • For requests requiring more than one test, send an additional 5 µg DNA per test ordered when possible.
  • DNA may be shipped at room temperature.
  • Label the tube with the composition of the solute, DNA concentration as well as the patient’s name, date of birth, and/or ID number.
  • We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.


(Delivery preferred Monday - Thursday)

  • PreventionGenetics should be notified in advance of arrival of a cell culture.
  • Culture and send at least two T25 flasks of confluent cells.
  • Some panels may require additional flasks (dependent on size of genes, amount of Sanger sequencing required, etc.). Multiple test requests may also require additional flasks. Please contact us for details.
  • Send specimens in insulated, shatterproof container overnight.
  • Cell cultures may be shipped at room temperature or refrigerated.
  • Label the flasks with the patient name, date of birth, and/or ID number.
  • We strongly recommend maintaining a local back-up culture. We do not culture cells.
loading Loading... ×